We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 81-100 of 346 results

  1. A Review of Calcitonin Gene-Related Peptide and Its Implications for Vestibular Disorders

    Purpose of review

    Calcitonin gene-related peptide (CGRP) is an inflammatory neuropeptide widely present throughout the body and involved in many...

    Richard Baron, Kristen K. Steenerson in Current Treatment Options in Neurology
    Article 23 May 2024

  2. Medikamentöse Anfallsbehandlung und Vorbeugung der Migräne

    Hartmut Göbel, Axel Heinze, ... Carl Göbel in Schmerzmedizin
    Article 04 November 2022

  3. The ultimate guide to the anti-CGRP monoclonal antibodies galaxy

    Background

    Anti-CGRP monoclonal antibodies have represented a real revolution in the field of headaches, being the result of an extraordinary process...

    Davide Mascarella, Eleonora Matteo, ... Sabina Cevoli in Neurological Sciences
    Article 20 June 2022

  4. Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review

    Background

    Many patients with chronic migraine do not achieve clinically meaningful improvement in their headache frequency with monotherapy. The...

    Amira Salim, Elise Hennessy, ... Ignacio F. Mata in CNS Drugs
    Article Open access 07 April 2024

  5. Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline

    Introduction

    Chronic headache due to the overuse of medication for the treatment of migraine attacks has a prevalence of 0.5–2.0%. This guideline...

    Hans-Christoph Diener, Peter Kropp, ... Christian Lampl in Neurological Research and Practice
    Article Open access 29 August 2022

  7. CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies

    Purpose of Review

    Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor have become part of the standard treatment for...

    Yen-Feng Wang, Shuu-Jiun Wang in Current Pain and Headache Reports
    Article 14 May 2022

  8. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase®

    Background

    Current evidence on the safety of calcitonin gene–related peptide antagonists (CGRP-A) in pregnancy for the treatment of both episodic and...

    Roberta Noseda, Francesca Bedussi, ... Chiara Zecca in The Journal of Headache and Pain
    Article Open access 19 January 2024

  9. The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression

    Background

    Migraine affects 1.1 billion people globally and is the second leading cause of disability worldwide. In clinical trials, treatment...

    Stewart J. Tepper, Jessica Cirillo, ... Peter McAllister in The Journal of Headache and Pain
    Article Open access 16 May 2023

  10. CGRP-Antikörper in der Migräneprophylaxe

    Migraine is associated with a high individual level of suffering. Therefore, an effective preventive treatment is highly important. The spectrum of...

    Till Hamann, Florian Rimmele, Tim Patrick Jürgens in Der Schmerz
    Article 18 January 2022

  11. Migräne - Diagnostik und Prophylaxe

    Elizabeth George, Andreas Straube, Katharina Kamm in MMW - Fortschritte der Medizin
    Article 28 September 2023

  12. Mode and site of action of therapies targeting CGRP signaling

    Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs...

    Alejandro Labastida-Ramírez, Edoardo Caronna, ... Jan Hoffmann in The Journal of Headache and Pain
    Article Open access 11 September 2023

  14. Alopezie durch Anti-CGRP-Substanzen?

    Hans-Christoph Diener in MMW - Fortschritte der Medizin
    Article 15 September 2023

  15. Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review

    Background

    Real-world data are accumulating on the effectiveness, tolerability and safety of anti-calcitonin gene-related peptide pathway monoclonal...

    Nicolas Vandenbussche, Karolina Pisarek, Koen Paemeleire in The Journal of Headache and Pain
    Article Open access 22 June 2023

  16. CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache

    Purpose of Review

    Chronic cluster headache (CH) substantially affects patients’ quality of life, and treatment remains challenging. The current...

    Shu-Ting Chen, Jr-Wei Wu in Current Pain and Headache Reports
    Article 26 July 2022

  17. Cardiovascular Disease and Migraine: Are the New Treatments Safe?

    Purpose of Review

    The authors present data on cardiovascular safety for the new acute and preventive migraine treatments including ditans, gepants,...

    Jennifer Robblee, Lauren K. Harvey in Current Pain and Headache Reports
    Article 25 June 2022

  19. Unmet Needs in Preventive Treatment of Migraine

    Migraine represents the most common cause of work disability in young women and the second one in the general population. Preventive treatment can...

    Enrico Bentivegna, Dilara Onan, Paolo Martelletti in Neurology and Therapy
    Article Open access 04 February 2023

  20. Modernes Migränemanagement

    Sonja-Maria Tesar in Schmerz Nachrichten
    Article 13 May 2024
Did you find what you were looking for? Share feedback.